Core Viewpoint - INmune Bio Inc. has successfully closed a registered direct offering of 3,000,000 shares at a price of $6.30 per share, generating approximately $19 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering was priced at-the-market under Nasdaq rules and was announced on June 27, 2025 [1]. - The gross proceeds from the offering are approximately $19 million, before deducting placement agent fees and other estimated offering expenses [2]. - A.G.P./Alliance Global Partners acted as the sole placement agent for the offering [2]. Group 2: Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [5]. - The company has three product platforms: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which is in clinical trials for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [5]. - The Natural Killer Cell Priming Platform, which includes INKmune® for cancer treatment, currently in trials for metastatic castration-resistant prostate cancer [5]. - The CORDStrom™ platform, which recently completed a trial for recessive dystrophic epidermolysis bullosa [5].